UniCel DxH 800 Coulter Cellular Analysis System and UniCel DxH 600 Coulter Cellular Analysis System 의 리콜

Department of Health, Therapeutic Goods Administration에 따르면, 해당 리콜 는 Australia 에서 Beckman Coulter Australia Pty Ltd 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

의료기기에 문제가 생겼을 경우 제조사가 이를 바로잡거나 시장에서 회수하는 조치를 말한다. 회수(Recall)는 의료기기에 결함이 있거나, 건강에 위협이 되거나, 또는 결함도 있고 건강에도 위협이 될 경우에 발생한다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Recall
  • 사례 ID
    RC-2017-RN-00556-1
  • 사례 위험등급
    Class I
  • 사례 시작날짜
    2017-05-16
  • 사례 국가
  • 사례 출처
    DHTGA
  • 사례 출처 URL
  • 비고 / 경고
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • 데이터 추가 비고
  • 원인
    There is a possibility of a data acquisition disruption that may cause an unusual light scatter event pattern for the white blood cell differential that may not have a system flag and/or message. the events associated with the unusual light scatter pattern may be incorrectly removed from analysis which can result in an erroneous differential result.In most cases, system flags and/or messages have accompanied the erroneous results, indicating the need to review the results. in rare instances, system flags and/or messages might be absent.
  • 조치
    Users are requested to: 1. Use all available features to assess patient results, including reference ranges, action and critical limits, instrument system flags, codes, messages, delta checks, and decision rules; 2. Follow all Instructions for Use (IFU) pertaining to flow cell error and warning messages, and ensure daily Shutdown is performed; 3. Follow your laboratory’s standard operating procedure for confirming unexpected results; 4. Communicate to your Laboratory Medical Director the need to avoid patient treatment based solely on any single test result, and to interpret all results in the context of other clinical and laboratory features; and 5. Consult with your Medical Director to determine if a retrospective review of results is warranted. In the interim, Beckman Coulter is working on a permanent resolution to detect and flag these unexpected light scatter patterns.

Device

Manufacturer